On October 19 2026, the US Food and Drug Administration (FDA) granted accelerated approval to dostarlimab (Jemperli) for adults with Stage II/III locally advanced rectal cancer that is microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR).

Recent analysis has seen positive interim results from the phase II AZUR-1 trial evaluating Jemperli (dostarlimab) monotherapy as a standalone treatment option in patients with stage II and III microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) locally advanced rectal cancer.

76% of patients with MSI-H/dMMR locally advanced rectal cancer achieved a complete response with patients experiencing no evidence of cancer following treatment with just Jemperli (dostarlimab).

Further to this, responders reported no disease recurrences after follow-up (median) of more than two years.

Serious adverse reactions occurred in 20% of patients receiving Jemperli and treatment was permanently discontinued due to adverse reactions in 3% of patients. The most common adverse reactions (≥15%) were fatigue, rash, diarrhoea, and pruritus (itchy skin).

Bowel Cancer Australia continues horizon scanning for new treatment options approved overseas and advocates for them to be indicated and subsidised for patients in Australia.

Published: October 24, 2026

Latest Articles